Tomuzotuximab is under clinical development by Glycotope and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tomuzotuximab’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tomuzotuximab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tomuzotuximab overview

Cetuximab biobetter (GT-MAB 5.2-GEX, CetuGEX) is under development for treatment of locally advanced and/or metastatic solid cancers, non-small cell lung cancer, gastric cancer, esophageal cancer, and metastatic colorectal cancer, renal cancer, breast cancer, gynecological cancer and squamous cell carcinoma of the head and neck. CetuGEX is glycosylated biobetter of cetuximab. The drug candidate is administered intravenously. It targets epidermal growth factor receptor (EGFR). It is a second generation chimeric monoclonal antibody developed based on the GlycoExpress technology.

Glycotope overview

Glycotope is a biotechnology company that is in clinical stage immuno-oncology which develops glyco-biology products. The company’s expression platform offers proprietary technologies such as glycobody and glycoexpress that allows the glycosylation of antibodies and glycoproteins in human metabolism. It also develops treatments for infertility and blood coagulation disorders. Glycotope’s oncology pipeline products are used for various cancers including ovarian, breast, lung, head and neck, gastric, non-small cell lung cancer and others. The company’s non-oncology pipeline products are used for in-vitro fertilization, Haemophilia and other indications. It operates in Berlin and Heidelberg. Glycotope is headquartered in Berlin, Germany.

Quick View Tomuzotuximab LOA Data

Report Segments
  • Innovator
Drug Name
  • Tomuzotuximab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.